earnings
confidence high
sentiment positive
materiality 0.85
Indivior Q1 net revenue $317M (+19% YoY); raises FY2026 guidance
Indivior Pharmaceuticals, Inc.
2026-Q1 EPS reported
$0.69
revenue$317,000,000
- Q1 GAAP net income $89M ($0.69 EPS); non-GAAP net income $123M ($0.96 EPS).
- SUBLOCADE net revenue $232M (+32% YoY) driven by 20% dispense unit growth.
- Record Q1 adjusted EBITDA $164M (+112% YoY); cash and investments $201M.
- Raised FY2026 guidance: net revenue $1.215-1.285B; adj. EBITDA $620-660M.
- Discontinued INDV-6001 development; INDV-2000 failed Ph2 OUD endpoint.